| Autor: |
Nicola S; SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy.; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Borrelli R; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Ridolfi I; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Bernardi V; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Borrelli P; SSD Dermatologia e Allergologia, Ospedale Beauregard, Via Vaccari, 5, 11100 Aosta, Italy., Guida G; Dipartimento di Scienze Cliniche e Biologiche, University o Torino, Regione Gonzole, 10, 10043 Orbassano, Italy., Antonelli A; SS Allergologia e Fisiopatologia Respiratoria, ASO Santa Croce e Carle, Via Michele Coppino, 26, 12100 Cuneo, Italy., Albera C; S.C. Pneumologia U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Corso Bramante, 88, 10126 Torino, Italy., Marengo S; SC Medicina Interna, AO Ordine Mauriziano di Torino, Largo Turati 62, 10128 Torino, Italy., Briozzo A; SC Medicina Interna, AO Ordine Mauriziano di Torino, Largo Turati 62, 10128 Torino, Italy., Norbiato C; SC Medicina Interna, AO Ordine Mauriziano di Torino, Largo Turati 62, 10128 Torino, Italy., Frazzetto AV; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Saad M; S.C. Pneumologia U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Corso Bramante, 88, 10126 Torino, Italy., Lo Sardo L; SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy.; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Bacco B; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Gallo Cassarino S; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Della Mura S; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Bagnasco D; Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy., Bucca C; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Rolla G; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy., Solidoro P; S.C. Pneumologia U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Corso Bramante, 88, 10126 Torino, Italy., Brussino L; SCDU Immunologia e Allergologia, AO Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy.; Department of Medical Sciences, University of Torino, C.so Dogliotti, 14, 10126 Torino, Italy. |
| Abstrakt: |
Introduction: Asthma, along with inhaled steroids, was initially considered a risk factor for worse clinical outcomes in COVID-19. This was related to the higher morbidity observed in asthma patients during previous viral outbreaks. This retrospective study aimed at evaluating the prevalence of asthma among patients admitted due to SARS-CoV-2 infection as well as the impact of inhaled therapies on their outcomes. Furthermore, a comparison between patients with asthma, COPD and the general population was made. Methods: All COVID-19 inpatients were recruited between February and July 2020 from four large hospitals in Northwest Italy. Data concerning medical history, the Charlson Comorbidity Index (CCI) and the hospital stay, including length, drugs and COVID-19 complications (respiratory failure, lung involvement, and the need for respiratory support) were collected, as well as the type of discharge. Results: patients with asthma required high-flow oxygen therapy (33.3 vs. 14.3%, p = 0.001) and invasive mechanical ventilation (17.9 vs. 9.5%, p = 0.048) more frequently when compared to the general population, but no other difference was observed. Moreover, asthma patients were generally younger than patients with COPD (59.2 vs. 76.8 years, p < 0.001), they showed both a lower mortality rate (15.4 vs. 39.4%, p < 0.001) and a lower CCI (3.4 vs. 6.2, p < 0.001). Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024). Discussion: Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay. In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities. |
